多塞塔克塞尔和吉姆奇塔宾调节非小细胞肺癌中的细胞效应和长非编码RNA配置文件
Andrei-Alexandru Tirpe1, Lajos Raduly1, Oana Zanoaga1
1Department of Genomics, MEDFUTURE Institute for Biomedical Research, Iuliu Hațieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.
International journal of molecular sciences
|December 11, 2025
概括
吉姆西塔 (GEM) 和多塞 (DOC) 化疗可以诱导细胞死亡,并影响非小细胞肺癌 (NSCLC) 细胞系的迁移. 这些药物还影响肺癌模型中的细胞周期,自和长非编码RNA表达.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 肺癌是全球癌症相关死亡的主要原因之一.
- 目前的指导方针建议在特定的非小细胞肺癌 (NSCLC) 患者群体中单一治疗gemcitabine (GEM) 或docetaxel (DOC).
- 了解这些化疗药物的细胞机制对于优化治疗至关重要.
研究的目的:
- 调查GEM和DOC在各种NSCLC细胞系中作为单一疗法的独特细胞效应.
- 分析GEM和DOC对亡,迁移,细胞周期,自和长非编码RNA (lncRNA) 表达的影响.
- 提供关于GEM和DOC在NSCLC中的药动力学作用的见解.
主要方法:
- 使用的NSCLC细胞系包括肺腺癌 (A549,CALU6) 和肺状细胞癌 (LUSC,H520,H1703).
- 评估了细胞效应,包括细胞亡,细胞迁移 (划伤试验),细胞循环停止和自活动.
- 分析了关键的lncRNAs (MALAT1,NEAT1,HOTAIR) 在对GEM和DOC治疗的反应中的表达.
主要成果:
- 在48小时内,在所有测试的NSCLC细胞系中,GEM和DOC诱导了细胞亡.
- 这两种化疗药物都影响了癌细胞迁移,并诱导了不同的细胞循环停止模式.
- 在LUSC线路中,GEM和DOC触发了自信号,GEM在CALU6.6中也表现出影响.
- 在对GEM和DOC的反应中观察到MALAT1,NEAT1和HOTAIR的变量表达.
结论:
- 在NSCLC模型中,GEM和DOC表现出不同的细胞效应.
- 这些化疗药物影响基本的癌症过程,如细胞亡,迁移和细胞周期进展.
- 这项研究强调了GEM和DOC调节lncRNA表达的潜力,提出了新的治疗途径.
关键词:
A54949 是一个A549的字体.这就是CALU6的计算.H1703 其他类型H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H520 H霍泰尔 (HOTAIR) 是一个古老的酒店.马拉特语 马拉特语在NEAT1中,NEAT1是NEEAT1的类型.在NSCLCLC中,我们可以看到NSCLCLC.灭症 (apoptosis) 是一种死亡的过程.自自是自的过程.多塞塔克塞尔 (Docetaxel) 是一种药物.杰姆西塔宾 (gemcitabine) 是一种药物.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
02:39lncRNA - Long Non-coding RNAs
3.5K
3.5K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K